Monday, Sanofi SA (NASDAQ:SNY) shared data from the IMROZ phase 3 study of Sarclisa, which enrolled 446 patients with newly diagnosed, transplant-ineligible multiple myeloma. The company says that IMROZ is the first global phase 3 study of an anti-CD38 monoclonal antibody in combination with standard-of-care VRd to significantly improve PFS and show deep responses in this patient population who often have poor prognoses. The results were shared in an oral presentation at the American Society of Clinical Oncology annual meeting. The use of Sarclisa in combination with VRd in transplant-ineligible NDMM is investigational. At the data cut-off of September 26, 2023, through the median follow-up of 59.7 months, the following were ...